Covid Vaccine Race

An interview on new survey data suggesting a majority of fertility and pregnant patients are not interested in the currently available vaccines.

State and federal officials confirmed Friday that promise for a reserve supply of vaccines meant for second doses is actually unavailable.

The American College of Physicians offered recommendations on the distribution and administration of vaccines.

This vaccine is meant to be delivered as a single dose administration as compared to other vaccines that have been authorized and in development that require a booster shot.

The Department of Health and Human Services is expected to announce the new guidelines at noon.

Newly published data shows just 0.6% of patients receiving the Moderna mRNA vaccine reported serious adverse events, a rate identical to that of the placebo group.

China has overtaken the US and is currently leading all countries in total vaccine administrations.

The agency warns SARS-CoV-2 mutations can trigger potential false negative results in molecular tests.

The international organization offers guidance on various groups and if they should be consider getting the vaccine.

In vitro data suggest the more transmissible mutations of the virus are nonetheless prevented by the mRNA vaccine.

The federal agency announces that of nearly 2 million vaccinations, only 21 total cases of severe reactions took place.

Chinese company’s investigational vaccine reported to be 78% effective.

European Medicines Agency exercises its option for increasing the confirmed order commitment by 80 million doses, bringing total to 160 million.

Allergists offer risk stratification approach to avoid rare allergic reaction to COVID-19 vaccines

The US and the world must appreciate the role of the pharmaceutical industry—the investigators, physicians and business leaders—who are rescuing the world from COVID-19. It’s the medical breakthrough of our lifetime.

In the first week of 2021, the US is currently leading all countries in total vaccine administrations, despite state-level distribution setbacks.

From vaccine studies to reopening institutions, pooled testing may be a hugely beneficial tool.

The global health agency provided current insights and advisories into 4 different variants observed during COVID-19 this year.

The newly published data show no patient given the two-dose mRNA vaccine has yet to report a case of severe COVID-19.

Though regulatory authorization has not been granted, the company intends to vaccinate up to 50 million people prior to the Lunar New Year.

The authorization recommends dosage intervals of between 4 and 12 weeks.

Trial to enroll up to 30000 volunteers across approximately 115 sites in the US and Mexico.

With the public beginning to get vaccinated, CDC published information for people in some medical categories and considerations on severe allergic reactions.

Vaccine manufacturer Valneva recently announced it was initiating a phase 1/2 trial in the United Kingdom.

The agreement could mean upwards of 70 million more doses for eligible patients in mid-2021.

Though research is pending, the CEO used simple science to explain why the mRNA vaccine may still prevent from the UK variant.

The VRBPAC voted 20-0 with 1 abstention to support the benefit-risk profile associated with mRNA-1273.

At the interim analysis, the mRNA-1273 vaccine was found to have an efficacy of 94.5% against confirmed COVID-19.

Up to 40% more doses—or, enough to vaccinate another person with two doses—has been observed in the vials distributed at the beginning of this week.